Vericel (NASDAQ:VCEL) Insider Sells 1,500 Shares of Stock

November 7, 2026 by InsiderTrades.com

Key Points

Insider Sean Flynn sold 15,000 Vericel shares for about $778,800 at an average price of $51.92, reducing his stake by 88.29% to 1,990 shares.
Vericel’s third-quarter results beat expectations: revenue rose 26.5% year over year to $85.37 million, and EPS was $0.27 versus analysts’ $0.06 estimate.
The company raised its 2026 revenue outlook to $344 million–$346 million and adjusted EBITDA margin guidance to 28%; shares opened Friday up 5.5% at $54.62.

Vericel Corporation (NASDAQ:VCEL - Get Free Report) insider Jonathan Siegal sold 1,500 shares of Vericel stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $52.90, for a total transaction of $79,350.00. Following the completion of the transaction, the insider directly owned 1,259 shares in the company, valued at $66,601.10. This represents a 54.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vericel Trading Up 5.5%

3 Major Earnings Winners You May Have Missed

Shares of NASDAQ VCEL traded up $2.84 during midday trading on Friday, reaching $54.62. The company's stock had a trading volume of 1,612,332 shares, compared to its average volume of 564,100. Vericel Corporation has a one year low of $28.95 and a one year high of $55.60. The company has a market cap of $2.80 billion, a price-to-earnings ratio of 85.35 and a beta of 1.08. The company has a 50 day moving average price of $41.01 and a 200 day moving average price of $38.90.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.21. The firm had revenue of $85.37 million during the quarter, compared to analysts' expectations of $77.95 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The firm's revenue for the quarter was up 26.5% compared to the same quarter last year. During the same period last year, the firm posted $0.10 earnings per share. Research analysts anticipate that Vericel Corporation will post 0.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

5 medical stocks growing earnings by triple digits

A number of analysts have commented on VCEL shares. Truist Financial set a $65.00 price objective on shares of Vericel in a research note on Friday. TD Cowen lifted their price objective on shares of Vericel from $55.00 to $58.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. Weiss Ratings reissued a "hold (c)" rating on shares of Vericel in a research note on Thursday, October 29th. HC Wainwright raised their target price on Vericel from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Friday. Finally, Wall Street Zen upgraded Vericel from a "buy" rating to a "strong-buy" rating in a report on Saturday. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $60.80.

Check Out Our Latest Stock Analysis on VCEL

More Vericel News

Here are the key news stories impacting Vericel this week:

Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Hedge Funds Weigh In On Vericel

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Vericel during the second quarter valued at $360,023,000. Aberdeen Group plc raised its stake in shares of Vericel by 204.7% during the 3rd quarter. Aberdeen Group plc now owns 2,164,250 shares of the biotechnology company's stock worth $86,873,000 after purchasing an additional 1,454,012 shares in the last quarter. William Blair Investment Management LLC acquired a new position in Vericel in the second quarter worth approximately $88,662,000. Bank of America Corp DE increased its holdings in Vericel by 19.7% in the first quarter. Bank of America Corp DE now owns 1,098,771 shares of the biotechnology company's stock worth $35,347,000 after buying an additional 180,761 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Vericel by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 844,755 shares of the biotechnology company's stock valued at $27,173,000 after acquiring an additional 29,135 shares in the last quarter.

Vericel Company Profile

(Get Free Report)

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient's own cells or biologic materials to support tissue repair and healing.

Vericel's primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.